The use of ovarian cancer cells from patients undergoing surgery to generate primary cultures capable of undergoing functional analysis

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  O'Donnell, Rachel L ^a,b   McCormick, Aiste ^b   Mukhopadhyay, Asima ^a,b   Woodhouse, Laura C ^b   Moat, Madeleine ^b   Grundy, Anna ^b   Dixon, Michelle ^b   Kaufman, Angelika ^a,b   Soohoo, San ^a,b   Elattar, Ahmed ^b   Curtin, Nicola J ^b   Edmondson, Richard J ^c  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; DNA; EPITHELIAL CELL ADHESION MOLECULE; MONOCLONAL ANTIBODY D2-40; VIMENTIN;

ARTICLE; ASCITES; CANCER CELL; CANCER SURGERY; CELL CULTURE; DNA REPAIR; FEMALE; FUNCTIONAL ASSESSMENT; GENETIC TRANSFECTION; HISTOPATHOLOGY; HOMOLOGOUS RECOMBINATION; HUMAN; OVARY CANCER; OVARY CARCINOMA; PRIMARY CULTURE; SOLID TUMOR;

EID: 84897145705     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090604     Document Type: Article

References (24)

1. Statistics NOf (2011) Mortality statistics: Deaths registered in 2010 (Series DR) Table 5.2. National Office for Statistics.
2. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, et al. (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361: 2099-2106.
3. Korch C, Spillman MA, Jackson TA, Jacobsen BM, Murphy SK, et al. (2012) DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecol Oncol 127: 241-248.
4. Dunfield LD, Shepherd TG, Nachtigal MW (2002) Primary culture and mRNA analysis of human ovarian cells. Biol Proced Online 4: 55-61. (Pubitemid 35450696)
5. Mukhopadhyay A, Elattar A, Cerbinskaite A, Wilkinson SJ, Drew Y, et al. (2010) Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res 16: 2344-2351.
6. Le Page C, Ouellet V, Madore J, Ren F, Hudson TJ, et al. (2006) Gene expression profiling of primary cultures of ovarian epithelial cells identifies novel molecular classifiers of ovarian cancer. Br J Cancer 94: 436-445. (Pubitemid 43237567)
7. Hennessy BT, Murph M, Nanjundan M, Carey M, Auersperg N, et al. (2008) Ovarian cancer: linking genomics to new target discovery and molecular markers-the way ahead. Adv Exp Med Biol 617: 23-40.
8. Hirte HW, Clark DA, Mazurka J, O'Connell G, Rusthoven J (1992) A rapid and simple method for the purification of tumor cells from ascitic fluid of ovarian carcinoma. Gynecol Oncol 44: 223-226.
9. Shepherd TG, Theriault BL, Campbell EJ, Nachtigal MW (2006) Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients. Nat Protoc 1: 2643-2649.
10. Lee EC (1991) Cytogenetic analysis of continuous cell lines In The ACT Cytogenetic Laboratory Manual: 107-148.
11. Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1: 1112-1116.
12. Abramoff M, Magelhaes P, Ram S (2004) Image processing with ImageJ. Biophoton Int 11: 36-42.
13. Znojek P (2011) PhD Thesis. Newcastle University.
14. Bau DT, Mau YC, Ding SL, Wu PE, Shen CY (2007) DNA double-strand break repair capacity and risk of breast cancer. Carcinogenesis 28: 1726-1730.
15. Ohashi A, Zdzienicka MZ, Chen J, Couch FJ (2005) Fanconi anemia complementation group D2 (FANCD2) functions independently of BRCA2-and RAD51-associated homologous recombination in response to DNA damage. J Biol Chem 280: 14877-14883. (Pubitemid 40562837)
16. Perez RP, Godwin AK, Handel LM, Hamilton TC (1993) A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines. Eur J Cancer 29A: 395-399. (Pubitemid 23025749)
17. Fong M, Kakar S (2009) Ovarian cancer mouse models: a summary of current models and their limitations. J Ovarian Res 2.
18. Bowtell DDL (2010) The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 10: 803-808.
19. Khalique L, Ayhan A, Weale ME, Jacobs IJ, Ramus SJ, et al. (2007) Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. The Journal of Pathology 211: 286-295. (Pubitemid 46172704)
20. Abelson S, Shamai Y, Berger L, Shouval R, Skorecki K, et al. (2012) Intratumoral Heterogeneity in the Self-Renewal and Tumorigenic Differentiation of Ovarian Cancer. Stem Cells 30: 415-424.
21. Kobel M, Turbin D, Kalloger S, Gao D, Huntsman D, et al. (2011) Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites. Int J Gyn Path 30: 366-371.
22. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, et al. (2005) Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 99: 267-277. (Pubitemid 41502830)
23. Souhami RL, Beverley PC, Bobrow LG, Ledermann JA (1991) Antigens of lung cancer: results of the second international workshop on lung cancer antigens. J Natl Cancer Inst 83: 609-612.
24. Marks A, Sutherland DR, Bailey D, Iglesias J, Law J, et al. (1999) Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. Br J Cancer 80: 569-578. (Pubitemid 29213215)